PRRT2 and neoplasm: Therefore, a substantial number of studies implicate that inhibition of PKC-mediated phosphorylation of KRas at the Ser181 residue, possibly in combination with agents that block calmodulin-mediated PI3K/Akt activation, could be a potential therapeutic target for KRAS-driven tumours (Figure 3).